[25] In this study, specimens from all blood donations collected in 2008 were screened for HBsAg, anti-HBc (HBV core antibody ... that routine infant hepatitis B vaccination, with 90% coverage ...

CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, ...

Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ETCompany ParticipantsConstantin Fest - Head of IREmma Walmsley - CEOLuke Miels ...

Story March 27 - Arbutus Biopharma: Arbutus is stripping back its workforce to just a “core team” needed to oversee mid-stage trials of the biotech's potential functional cure for hepatitis B.

derived from the roundleaf bat hepatitis B virus core antigen (RBHBcAg); the candidate molecule was named CR-T3-SEQ13. Multiple copies of epitopes on the surface of this particulate antigen promote ...

These are still high on the list of AZ’s core focus today ... this time to develop small-molecule protein kinase B (PKB) to further contribute in the fight against cancer.

Objective: This study aimed to compare the prevalence of serum hepatitis B virus (HBV) markers in Inner Mongolia between 2006 and 2020. Methods: The same sampling process was used in investigations ...

For hepatitis B core antigen (HBcAg) staining, cells were fixed, permeabilised and blocked overnight at 4°C. Cells were stained with a combination of polyclonal rabbit HBc-antibody (DakoCytomation, ...

The Hepatitis B virus is a leading cause of liver-related morbidity and mortality, particularly through chronic hepatitis B (CHB), which can progress to cirrhosis and liver cancer. While most ...